{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:06:01Z","timestamp":1740146761958,"version":"3.37.3"},"reference-count":24,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T00:00:00Z","timestamp":1639094400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011326","name":"Shiga University of Medical Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Purpose<\/jats:title>\n<jats:p>To evaluate the short-term effect on body weight (BW) gain after intravitreal bevacizumab (IVB) for retinopathy of prematurity (ROP).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>This was a retrospective 1:1 matched case-control study. Infants with ROP treated by IVB or photocoagulation (PC) at Shiga University of Medical Science Hospital between April 2010 and December 2019 were included in the study. To match BWs at treatment between the IVB and PC groups, 1:1 matching for BWs at treatment within 100 g was performed. The BW gains for the 7 days before treatment (pre-treatment week), the 7 days after treatment (first post-treatment week), and the period from 7 to 14 days after treatment (second post-treatment week) were compared between the IVB and PC groups.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Following 1:1 matching, 13 infants in both groups were enrolled in the analysis. The weekly BW gain for the first post-treatment week was significantly lower in the IVB group compared with the PC group (86 g vs. 145 g; P = 0.046), whereas the weekly BW gains for the pre-treatment week (173 g vs. 159 g; P = 0.71) and the second post-treatment week (154 g vs. 152 g; P = 0.73) were comparable between the two groups. The short-term inhibitive effect of IVB on BW gain was particularly observed in infants weighing less than 1500 g at treatment (&lt;1500 g: 47 g vs. \u22651500 g: 132 g; P = 0.03).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>IVB could have a short-term inhibitive effect on BW gain in infants with ROP, and this effect is more likely to occur in infants with a lower BW at the time of treatment.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0261095","type":"journal-article","created":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T18:30:22Z","timestamp":1639161022000},"page":"e0261095","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effect of intravitreal bevacizumab for retinopathy of prematurity on weight gain"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6120-2392","authenticated-orcid":true,"given":"Shumpei","family":"Obata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Ichiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riko","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Kakinoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitsugu","family":"Saishin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahide","family":"Yanagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Maruo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahito","family":"Ohji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,12,10]]},"reference":[{"issue":"2","key":"pone.0261095.ref001","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.earlhumdev.2007.11.009","article-title":"Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control","volume":"84","author":"C. Gilbert","year":"2008","journal-title":"Early Hum Dev"},{"issue":"6","key":"pone.0261095.ref002","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.ophtha.2007.07.028","article-title":"Progression of myopia and high myopia in the early treatment for retinopathy of prematurity study: findings to 3 years of age","volume":"115","author":"GE Quinn","year":"2008","journal-title":"Ophthalmology"},{"issue":"2","key":"pone.0261095.ref003","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jaapos.2012.10.025","article-title":"Progression of myopia and high myopia in the Early Treatment for Retinopathy of Prematurity study: findings at 4 to 6 years of age","volume":"17","author":"GE Quinn","year":"2013","journal-title":"J AAPOS"},{"issue":"3","key":"pone.0261095.ref004","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3928\/0191-3913-20070301-10","article-title":"Effect of diode laser retinal ablative therapy for threshold retinopathy of prematurity on the visual field: results of goldmann perimetry at a mean age of 11 years","volume":"44","author":"E McLoone","year":"2007","journal-title":"J Pediatr Ophthalmol Strabismus"},{"issue":"12","key":"pone.0261095.ref005","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial","volume":"121","author":"Early Treatment For Retinopathy Of Prematurity Cooperative G","year":"2003","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"pone.0261095.ref006","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"HA Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"pone.0261095.ref007","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial","volume":"132","author":"MM Geloneck","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"pone.0261095.ref008","doi-asserted-by":"crossref","first-page":"e0129383","DOI":"10.1371\/journal.pone.0129383","article-title":"A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity","volume":"10","author":"L Pertl","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"pone.0261095.ref009","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity","volume":"153","author":"T Sato","year":"2012","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"pone.0261095.ref010","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00417-017-3878-4","article-title":"Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity","volume":"256","author":"CY Huang","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"pone.0261095.ref011","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00417-015-2996-0","article-title":"Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab","volume":"254","author":"Y Zhou","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"pone.0261095.ref012","doi-asserted-by":"crossref","first-page":"e21390","DOI":"10.1096\/fj.202002414R","article-title":"The systemic antiangiogenic effect of intravitreal aflibercept injection in a mouse model of retinopathy of prematurity","volume":"35","author":"Y Ichiyama","year":"2021","journal-title":"FASEB J"},{"issue":"1","key":"pone.0261095.ref013","first-page":"61","article-title":"Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity","volume":"22","author":"KA Kennedy","year":"2018","journal-title":"J AAPOSPubMed Central PMCID"},{"issue":"2","key":"pone.0261095.ref014","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1167\/iovs.14-15842","article-title":"Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity","volume":"56","author":"L Kong","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"pone.0261095.ref015","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2015-3218","article-title":"Neurodevelopmental Outcomes Following Bevacizumab Injections for Retinopathy of Prematurity","volume":"137","author":"J Morin","year":"2016","journal-title":"Pediatrics"},{"issue":"4","key":"pone.0261095.ref016","first-page":"295","article-title":"Failure to Thrive: A Practical Guide","volume":"94","author":"GJ Homan","year":"2016","journal-title":"Am Fam Physician"},{"key":"pone.0261095.ref017","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1471-2431-13-59","article-title":"A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants","volume":"13","author":"TR Fenton","year":"2013","journal-title":"BMC Pediatr"},{"issue":"3","key":"pone.0261095.ref018","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10456-019-09662-4","article-title":"Anti-secretogranin III therapy of oxygen-induced retinopathy with optimal safety","volume":"22","author":"F Tang","year":"2019","journal-title":"Angiogenesis"},{"issue":"6","key":"pone.0261095.ref019","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1001\/jamaophthalmol.2017.1055","article-title":"Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing Study.","volume":"135","author":"DK Wallace","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"pone.0261095.ref020","article-title":"Secondary 12-Month Ocular Outcomes of a Phase 1 Dosing Study of Bevacizumab for Retinopathy of Prematurity","author":"ER Crouch","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"pone.0261095.ref021","article-title":"Neurodevelopmental outcomes following bevacizumab treatment for retinopathy of prematurity: a systematic review and meta-analysis","author":"M Kaushal","year":"2020","journal-title":"J Perinatol"},{"issue":"3","key":"pone.0261095.ref022","doi-asserted-by":"crossref","first-page":"e0230678","DOI":"10.1371\/journal.pone.0230678","article-title":"Neurodevelopmental outcomes following intravitreal bevacizumab injection in Japanese preterm infants with type 1 retinopathy of prematurity","volume":"15","author":"M Arima","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"pone.0261095.ref023","doi-asserted-by":"crossref","first-page":"e0148019","DOI":"10.1371\/journal.pone.0148019","article-title":"Neurodevelopmental Outcomes in Infants with Retinopathy of Prematurity and Bevacizumab Treatment.","volume":"11","author":"R Lien","year":"2016","journal-title":"PLoS One"},{"key":"pone.0261095.ref024","article-title":"Neurodevelopmental Outcomes after Intravitreal Bevacizumab Therapy for Retinopathy of Prematurity","author":"Y-Y Fan","year":"2019","journal-title":"Ophthalmology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0261095","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T18:30:49Z","timestamp":1639161049000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0261095"}},"subtitle":[],"editor":[{"given":"Vikas","family":"Khetan","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,12,10]]},"references-count":24,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0261095","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2021,12,10]]}}}